STAAR Surgical Company's stock surged 15.65% during pre-market trading on Thursday, following the release of its first-quarter 2026 financial results that significantly exceeded market expectations.

The intraocular lens maker reported a swing to profitability with Q1 earnings of $0.10 per diluted share, beating consensus estimates that anticipated a loss. Revenue more than doubled year-over-year to a record $93.5 million, well above analyst forecasts. The company attributed the strong performance primarily to a recovery in demand in China, normalization of distributor inventory, and the successful launch of its EVO+ ICL product in the region.

Following the earnings release, multiple analysts raised their price targets on the stock. Piper Sandler increased its target to $33 from $16, while Canaccord Genuity raised its target to $32 from $27, reflecting increased confidence in the company's growth trajectory and its plan to supply the Chinese market from its Swiss facility to avoid import tariffs.